Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521413 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
A Phase 1 study of Advanced Solid Malignancies, sponsored by Treadwell Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 170
- Enrollment target
- 13
- Study locations
NCT04521413 is a Phase 1 study of Advanced Solid Malignancies that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 170 participants, below the 217-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (22% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT04521413, a Phase 1 study of Advanced Solid Malignancies, is active but no longer recruiting, sponsored by Treadwell Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 170 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG CFI-402411
Study Locations (13)
California
- University of California San Diego - La Jolla
- The Angeles Clinic - Los Angeles
Texas
- MD Anderson - Houston
- START - San Antonio - San Antonio
Ontario
- The Ottawa Hospital - Ottawa
- Princess Margaret Cancer Centre - Toronto
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists - Sarasota
Michigan
- START - Mid-West - Grand Rapids
Tennessee
- SCRI - Nashville - Nashville
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04521413
The ClinicalTrials.gov registry entry for NCT04521413 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (22% lower). The listed sponsor is Treadwell Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04521413 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT04521413 about?
NCT04521413 is a clinical study titled "Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies". The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
What is the current status of trial NCT04521413?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2020-08-31. Estimated completion is 2025-12.
What conditions does trial NCT04521413 study?
This clinical trial studies the following conditions: Advanced Solid Malignancies.
What interventions are being tested in trial NCT04521413?
The interventions under investigation include: Pembrolizumab (DRUG), CFI-402411 (DRUG).
Who is sponsoring clinical trial NCT04521413?
This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04521413 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.